BIOWAMED
DEAD

Serial Number

78214938

Owner

KYOWA HAKKO KOGYO CO., LTD.

Attorney

LAWRENCE E. ABELMAN

Filing Date

Feb 14, 2003

Add to watchlist:

No watchlists yet
View on USPTO

BIOWAMED Trademark

Serial Number: 78214938

BIOWAMED is a trademark filed by KYOWA HAKKO KOGYO CO., LTD. on February 14, 2003. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

KYOWA HAKKO KOGYO CO., LTD. (51 trademarks)

CHIYODA-KU, TOKYO , JP

Entity Type: 03

Trademark Details

Filing Date

February 14, 2003

Registration Date

Not Registered

Published for Opposition

June 22, 2004

Goods & Services

Custom manufacturing of antibodies, fragments of such antibodies and derivatives of such antibodies; custom manufacturing of cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; custom manufacturing of transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; custom manufacturing of host cells

Cells for medical or clinical use that manufacture antibodies, fragments of antibodies or derivatives of antibodies; cells for medical or clinical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; host cells for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidium in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and/or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, antiparkinsonism drugs, minor tranquilizers, and antianxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, vitamins, anti-bacterial preparations, mucolytic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extracorporeal diagnostic reagents for medical use, in vitro X-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases

Biochemicals, namely, monoclonal antibodies, fragments of such antibodies and derivatives of such antibodies for in vitro scientific or research use; cells for scientific, laboratory or medical research cells that manufacture antibody, fragment of antibody or derivatives of antibody; cells for scientific, laboratory or medical research, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; host cells for scientific, laboratory or medical research

Contract development of antibodies, fragments of such antibodies and derivatives of such antibodies; contract development of cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; contract development of transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; contract development of host cells

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
May 16, 2006 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 16, 2006 ABN6
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 7, 2006 CHAN
PAPER RECEIVED
Feb 7, 2006 MAIL
SOU EXTENSION 2 GRANTED
Sep 7, 2005 EX2G
SOU EXTENSION 2 FILED
Sep 7, 2005 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 7, 2005 EEXT
SOU EXTENSION 1 GRANTED
Apr 19, 2005 EX1G
SOU EXTENSION 1 FILED
Mar 10, 2005 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 10, 2005 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Sep 14, 2004 NOAM
PUBLISHED FOR OPPOSITION
Jun 22, 2004 PUBO
NOTICE OF PUBLICATION
Jun 2, 2004 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 14, 2004 CNSA
ASSIGNED TO EXAMINER
Mar 17, 2004 DOCK
ASSIGNED TO EXAMINER
Mar 3, 2004 DOCK
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 2, 2004 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 2, 2004 TROA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 9, 2004 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 9, 2004 TROA
NON-FINAL ACTION MAILED
Aug 12, 2003 CNRT
ASSIGNED TO EXAMINER
Aug 11, 2003 DOCK